Amicus (FOLD) has received a new Hold rating, initiated by Morgan Stanley analyst, Maxwell Skor.
Maxwell Skor has given his Hold rating due to a combination of factors influencing Amicus Therapeutics’ current and future performance. The company is focusing on the launch and growth of its two main therapies, Galafold and Pombiliti + Opfolda (PomOp), which are crucial for its revenue trajectory. While Galafold has a strong market presence with over 65% of the global market share for amendable genetic variants of Fabry disease, its growth potential is somewhat limited as mature markets are nearing saturation.
Additionally, the company has set ambitious revenue growth targets for 2025, with a significant increase expected from PomOp. However, the realization of these targets depends on successful market penetration and overcoming competitive challenges. Furthermore, ongoing legal proceedings with Aurobindo could impact the company’s financial outlook. These elements, combined with management’s guidance towards achieving GAAP profitability by the second half of 2025, contribute to the Hold rating, reflecting a balanced view of potential risks and opportunities.
FOLD’s price has also changed moderately for the past six months – from $11.650 to $9.020, which is a -22.58% drop .
Questions or Comments about the article? Write to editor@tipranks.com